Olimab 60mg injection | Denosumab 60mg Apple pharmaceuticals
Olimab 60mg injection (Denosumab)
Olimab 60mg belongs to novel, fully human IgG2 monoclonal antibody especially to receptor activator of nuclear factor kappa-B ligand (RANKL), restrain bone resorption markers in patients with a difference of metastatic tumors and is being examined in multiple clinical trials for the Olimab 60mg inhibition and treatment of bone metastases.
Chemically, it exists of 2 heavy and 2 light chains. Each light chain contains of 215 amino acids.
Each heavy chain contains of 448 amino acids with Olimab 60mg 4 intramolecular disulfides.
Chemically, it exists of 2 heavy and 2 light chains. Each light chain contains of 215 amino acids.
Each heavy chain contains of 448 amino acids with Olimab 60mg 4 intramolecular disulfides.
PRESCRIBED
Treatment for patients having postmenopausal women with Olimab 60mg osteoporosis at high risk for fracture.
Treatment for patients with increase bone mass in men at more risk for fracture getting androgen deprivation therapy for non-metastatic prostate cancer.
Treatment for patients having to increase bone mass in Olimab 60mg women at more risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.
Treatment for patients with increase bone mass in men at more risk for fracture getting androgen deprivation therapy for non-metastatic prostate cancer.
Treatment for patients having to increase bone mass in Olimab 60mg women at more risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.
DOSAGE
For adult :
Osteoporosis :
60mg SC (subcutaneously) once every 6 months
Injection of drug should be done in upper arm, upper thigh or abdomen
Giant Cell Tumor of bone :
120mg SC, every 4 weeks with additional 120mg doses on days 8 and 15 of the 1st month treatment Olimab 60mg
Injection of drug should be done in upper arm, upper thigh or abdomen
Osteolytic Bone Metastases of Solid Tumors :
120mg subcutaneously every 4 weeks
Injection of drug should be done in upper arm, upper thigh or abdomen
Hypercalcemia :
Dose of 120mg Olimab 60mg tablet given SC, every 4 weeks with additional 120mg doses on days 8 and 15 of the 1st month treatment Injection of drug should be done in upper arm, upper thigh or abdomen
Dosage and administration in pediatric :
13 years and older and 45kg or more
Giant Cell Tumor of bone :
Dose of 120mg Olimab tablet given SC, every 4 weeks with additional 120mg doses on days 8 and 15 of the 1st month treatment OVERDOSE: Olimab overdose has no overdose. If occurs seek to emergency department and call poison control
Osteoporosis :
60mg SC (subcutaneously) once every 6 months
Injection of drug should be done in upper arm, upper thigh or abdomen
Giant Cell Tumor of bone :
120mg SC, every 4 weeks with additional 120mg doses on days 8 and 15 of the 1st month treatment Olimab 60mg
Injection of drug should be done in upper arm, upper thigh or abdomen
Osteolytic Bone Metastases of Solid Tumors :
120mg subcutaneously every 4 weeks
Injection of drug should be done in upper arm, upper thigh or abdomen
Hypercalcemia :
Dose of 120mg Olimab 60mg tablet given SC, every 4 weeks with additional 120mg doses on days 8 and 15 of the 1st month treatment Injection of drug should be done in upper arm, upper thigh or abdomen
Dosage and administration in pediatric :
13 years and older and 45kg or more
Giant Cell Tumor of bone :
Dose of 120mg Olimab tablet given SC, every 4 weeks with additional 120mg doses on days 8 and 15 of the 1st month treatment OVERDOSE: Olimab overdose has no overdose. If occurs seek to emergency department and call poison control
MECHANISM
Olimab 60mg tablet linked to RANKL, a protein which is specific for the formation, function and survival of osteoclasts, the cells necessary for bone resorption. Olimab 60mg prohibits osteoclast formation, function and survival hence, reducing bone resorption and raising bone mass and strength of the bone.
Peak plasma concentration: 6.75mcg/mL
Tmax : 10days
Without aggregation in Olimab pharmacokinetics with duration was noticed upon multiple dosing of 60 mg SC administered once every 6 months.
Pharmacokinetics of Olimab will not affected by the binding antibodies formation.
Half-life is 25.4 days.
Peak plasma concentration: 6.75mcg/mL
Tmax : 10days
Without aggregation in Olimab pharmacokinetics with duration was noticed upon multiple dosing of 60 mg SC administered once every 6 months.
Pharmacokinetics of Olimab will not affected by the binding antibodies formation.
Half-life is 25.4 days.
PRECAUTION
• Before to start treatment with Olimab, discuss with the doctor about any other regimens you are using (including over-the-counter drugs, vitamins, or herbal remedies). Do not take aspirin or products containing aspirin unless your doctor permits this.
• Olimab injection may improve the negative effects of immuno-suppressants. Especially the risk for serious infections may be increased. Inform your doctor of any immuno-suppressive drugs you early consume.
• Not to receive any type of vaccination without your doctor's consultation while admonishing denosumab.
• Use in pregnancy only if benefit to mother outweighs risk to fetus. Consult with doctor before the treatment
• During Olimab treatment do not breastfeed your infants.
• Olimab injection may improve the negative effects of immuno-suppressants. Especially the risk for serious infections may be increased. Inform your doctor of any immuno-suppressive drugs you early consume.
• Not to receive any type of vaccination without your doctor's consultation while admonishing denosumab.
• Use in pregnancy only if benefit to mother outweighs risk to fetus. Consult with doctor before the treatment
• During Olimab treatment do not breastfeed your infants.
DRUG INTERACTION
No formal drug-drug interaction with denosumab during trials.
When interacting with some anticancer drug, orthopedic drugs, vaccines will lead to risk of adverse effects can be increased
When interacting with some anticancer drug, orthopedic drugs, vaccines will lead to risk of adverse effects can be increased
CONTRAINDICATION
Olimab is contraindicated in patients having Hypocalcemia, Pregnancy, Hypersensitivity
STORAGE
Store at 2℃ to 8℃ in the original container, avoid freeze
Before to administration keep at room temperature
Olimab protect from direct light and heat.
Before to administration keep at room temperature
Olimab protect from direct light and heat.
SIDE EFFECTS
Common side effects for the patient taking Olimab 60mg as follows :
Fatigue, Muscle weakness, Phosphorus level reduced in blood, Nausea
Less common side effects for patients taking Olimab :
Dyspnea, Hypocalcemia, Cough, Arthralgia, Limb pain, Eczema, Headache
Fatigue, Muscle weakness, Phosphorus level reduced in blood, Nausea
Less common side effects for patients taking Olimab :
Dyspnea, Hypocalcemia, Cough, Arthralgia, Limb pain, Eczema, Headache
MISSED DOSE
Take the dose immediately before next dose duration, then left off the missed dose and continue regular schedule. Avoid taking double dose at same time.
Please consult the doctor for further information.
Please consult the doctor for further information.
Comments
Post a Comment